LDL-C – Talk Bio

Merck’s Oral PCSK9 Inhibitor Enlicitide Significantly Reduces LDL Cholesterol in Phase 3 Trials

2 months ago talkbio0Tagged Administration of prophylactic statin, cholesterol, CORALreef, CORALreef AddOn, enlicitide, HeFH, Hypercholesterolemia, Familial, Hyperlipidemia, LDL-C, Merck, Oral Therapy, PCSK9 inhibitor

Merck; PCSK9 inhibitor; enlicitide; phase 3 trials; cholesterol; LDL-C; oral therapy; hyperlipidemia; familial hypercholesterolemia; CORALreef HeFH; CORALreef AddOn; statin therapy

NewAmsterdam’s pooled Phase 3 data; C4 seeks partners for solid tumor degrader

3 months ago talkbio0Tagged BROADWAY, Cardiovascular Diseases, LDL-C, NewAmsterdam, Obicetrapib, Pooled Sample

Pooled Sample, Obicetrapib, BROADWAY, NewAmsterdam, LDL-C, Cardiovascular Diseases

Solbinsiran Demonstrates Significant Lipid Reductions in Phase 2 Trial for Mixed Dyslipidemia

4 months ago talkbio0Tagged Apolipoproteins B, Eli, Eli Lilly, LDL-C, RNA, Small Interfering, solbinsiran, Triglycerides

Solbinsiran, siRNA, mixed dyslipidemia, Eli Lilly, PROLONG-ANG3, apolipoprotein B, LDL-C, triglycerides

Novartis Expands Leqvio’s Potential After Successful Phase III Study Demonstrates Significant Cholesterol Reduction

11 months ago talkbio0Tagged Atherosclerosis, Cardiovascular Diseases, cholesterol, inclisiran, LDL-C, Leqvio, Novartis, Phase 3 Clinical Trials

Novartis, Leqvio, inclisiran, cholesterol reduction, Phase III study, ASCVD, LDL-C, cardiovascular disease